AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
PHOENIX, ARIZ. -- Valproate used as a mood stabilizer in bipolar disorder can cause polycystic ovary syndrome in about 10% of the women who take it, according to study results presented by Dr. Hadine Joffe of Harvard Medical School, Boston.
The results suggest that all women starting valproate should, at the very least, be warned about the possibility of developing polycystic ovary syndrome (PCOS). Physicians should closely monitor women on valproate, and should look for such signs of PCOS as oligomenorrhea, acne, and hirsutism, Dr. Joffe said at a meeting of the New Clinical Drug Evaluation Unit sponsored by the National Institute of Mental Health.
The study, which was ancillary to the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), included 230 women evaluated for treatment-emergent PCOS. A total of 86 of those women were taking valproate; 144 women were taking other mood stabilizers, including lithium, lamotrigine, topiramate, gabapentin, carbamazepine, and oxcarbazepine.
Of the 86 women taking valproate, 9 (10.5%) developed PCOS after starting the drug, compared with 2 (1.4%) of the 144 women taking other mood stabilizers, representing a relative risk for the disorder of 7.5 in the women taking valproate. The difference between groups was statistically significant.
Two possible risk factors emerged that may increase the chance that a woman taking valproate will develop PCOS. Women in the valproate group tended both to be younger and to be using antipsychotics, ...
Source: HighBeam Research, Risk highest in first year: valproate use related to PCOS in bipolar...